Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;40(3):138-50.
doi: 10.1007/s12016-010-8197-z.

Urinary biomarkers in lupus nephritis

Affiliations
Review

Urinary biomarkers in lupus nephritis

Joyce Reyes-Thomas et al. Clin Rev Allergy Immunol. 2011 Jun.

Abstract

Renal involvement in patients with systemic lupus erythematosus in the form of severe lupus nephritis is associated with a significant burden of morbidity and mortality. Conventional laboratory biomarkers in current use have not been very successful in anticipating disease flares, predicting renal histology, or decreasing unwanted outcomes. Since early treatment is associated with improved clinical results, it is thus essential to identify new biomarkers with substantial predictive power to reduce the serious sequelae of this difficult to control lupus manifestation. Indeed, considerable efforts and progress have been made over the last few years in the search for novel biomarkers. Since urinary biomarkers are more easily obtainable with much less risk to the patient than repeat renal biopsies, and these may more accurately discern between renal disease and other organ manifestations than their serum counterparts, there has been tremendous interest in studying new candidate urine biomarkers. Below, we review several promising urinary biomarkers under investigation, including total proteinuria and microalbuminuria, urinary proteomic signatures, and the individual inflammatory mediators interleukin-6, vascular cell adhesion molecule-1, CXCL16, IP-10, and tumor necrosis factor-like weak inducer of apoptosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Reproduced with permission from the Journal of Immunology, Copyright 2007. The American Association of Immunologists, Inc. [61]. Patients with active renal systemic lupus erythematosus (SLE) have significantly increased concentrations of urinary vascular cell adhesion molecule-1, CXCL16, tumor necrosis factor receptor-1, and P-selectin. Indicated p values pertain to Student’s t test or Mann–Whitney U test comparisons of each subject group vs. mild-active, non-renal SLE (*p<0.05, **p<0.01, ***p<0.001)
Fig. 2
Fig. 2
Reproduced with permission from Arthritis Research and Therapy [90]. Urinary TWEAK levels are significantly lower in systemic lupus erythematosus patients without lupus nephritis (a), and the log of urinary TWEAK correlates with increasing Systemic Lupus Erythematosus Disease Activity Index scores (b). *p<0.05

Similar articles

Cited by

References

    1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–424. - PubMed
    1. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982–1995. Arch Intern Med. 2000;160:3136–3140. - PubMed
    1. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36:63–67. - PMC - PubMed
    1. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046–2051. - PubMed
    1. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563–1569. - PubMed